Abstract:Objective To develop an HIV-1 AE recombinant envelope based vaccine since this recombinant has been accounted for high percent of sexual transmitted HIV-1 prevalence.Methods A recombinant Tiantan vaccinia based vaccines rVVT140AE expressing envelope gp140 from a circulating recombinant clade 97CNGX2F(HIV-1 AE2F) was constructed.DNA vaccine expressing gp140 and rVVT140AE was used to immunize mice with a prime/boost strategy.Mice were sacrificed 2 weeks after the final inoculation,then specific antibody titer and T cell responses were measured separately.Results The titers of env-specific antibodies elicited by this vaccines ranged from 3 200 to 51 200,with an geometric average at 11 143.Total T cell responses measured by ELISPOT was(1 918±442) SFCs/106 splenocytes with the responses against four peptide pools env1,env2,env3,env4 at(1 280±330) SFCs/106 splenocytes,(66±16) SFCs/106 splenocytes,(163±34) SFCs/106 splenocytes and(409±96) SFCs/106 splenocytes,which were all significantly higher than mock control group(10 SFCs/106 splenocytes).Conclusions The HIV-1 AE2F envelope gp140 recombinant vaccinia virus vaccine can be used for HIV-1 strains candidate vaccine immunogen.

Construction and Immunogenicity Analysis of a Vaccine Against HIV-1 AE Recombinant